Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
P Thoueille, E Choong, M Cavassini… - Journal of …, 2022 - academic.oup.com
The long-acting antiretroviral cabotegravir and rilpivirine combination has just received FDA,
EMA and Health Canada approval. This novel drug delivery approach is about to …
EMA and Health Canada approval. This novel drug delivery approach is about to …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel
Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …
Combination anti-HIV antibodies provide sustained virological suppression
MC Sneller, J Blazkova, JS Justement, V Shi… - Nature, 2022 - nature.com
Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …
However, eradication of the virus in individuals with HIV has not been possible to date …
First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an …
KA Christopoulos, J Grochowski… - Clinical Infectious …, 2023 - academic.oup.com
Background Long-acting injectable antiretroviral therapy (LAI-ART) is approved for treatment-
naive or experienced people with human immunodeficiency virus (HIV; PWH) based on …
naive or experienced people with human immunodeficiency virus (HIV; PWH) based on …
Expanded multivariable models to assist patient selection for long-acting cabotegravir+ rilpivirine treatment: clinical utility of a combination of patient, drug …
Background Previously reported post hoc multivariable analyses exploring predictors of
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
AG Cutrell, JM Schapiro, CF Perno, DR Kuritzkes… - Aids, 2021 - journals.lww.com
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed
intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here …
intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …
H Jaeger, ET Overton, G Richmond, G Rizzardini… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …
months might address the challenges associated with daily oral antiretroviral therapy. The …
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase …
Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …
virologically suppressed from daily oral standard of care to monthly long-acting …